Quantitative phenotypic and pathway profiling guides rational drug combination strategies. Dawson, J. C. and Carragher, N. O. Front.~Pharmacol., 5:118--125, 2014.
doi  abstract   bibtex   
Advances in target-based drug discovery strategies have enabled drug discovery groups in academia and industry to become very effective at generating molecules that are potent and selective against single targets. However, it has become apparent from disappointing results in recent clinical trials that a major challenge to the development of successful targeted therapies for treating complex multifactorial diseases is overcoming heterogeneity in target mechanism among patients and inherent or acquired drug resistance. Consequently, reductionist target directed drug-discovery approaches are not appropriately tailored toward identifying and optimizing multi-targeted therapeutics or rational drug combinations for complex disease. In this article, we describe the application of emerging high-content phenotypic profiling and analysis tools to support robust evaluation of drug combination performance following dose-ratio matrix screening. We further describe how the incorporation of high-throughput reverse phase protein microarrays with phenotypic screening can provide rational drug combination hypotheses but also confirm the mechanism-of-action of novel drug combinations, to facilitate future preclinical and clinical development strategies.
@article{Dawson:2014bh,
	Abstract = {Advances in target-based drug discovery strategies have enabled drug discovery groups in academia and industry to become very effective at generating molecules that are potent and selective against single targets. However, it has become apparent from disappointing results in recent clinical trials that a major challenge to the development of successful targeted therapies for treating complex multifactorial diseases is overcoming heterogeneity in target mechanism among patients and inherent or acquired drug resistance. Consequently, reductionist target directed drug-discovery approaches are not appropriately tailored toward identifying and optimizing multi-targeted therapeutics or rational drug combinations for complex disease. In this article, we describe the application of emerging high-content phenotypic profiling and analysis tools to support robust evaluation of drug combination performance following dose-ratio matrix screening. We further describe how the incorporation of high-throughput reverse phase protein microarrays with phenotypic screening can provide rational drug combination hypotheses but also confirm the mechanism-of-action of novel drug combinations, to facilitate future preclinical and clinical development strategies.},
	Author = {Dawson, John C. and Carragher, Neil O.},
	Date-Added = {2014-09-26 02:48:23 +0000},
	Date-Modified = {2014-09-26 02:49:06 +0000},
	Doi = {10.3389/fphar.2014.00118},
	Journal = {Front.~Pharmacol.},
	Journal-Full = {Frontiers in pharmacology},
	Keywords = {drug combinations; high-content; network pharmacology; phenotypic screening; proteomics},
	Pages = {118--125},
	Pmc = {PMC4035564},
	Pmid = {24904421},
	Pst = {epublish},
	Title = {Quantitative phenotypic and pathway profiling guides rational drug combination strategies},
	Volume = {5},
	Year = {2014},
	Bdsk-Url-1 = {http://dx.doi.org/10.3389/fphar.2014.00118}}
Downloads: 0